These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
307 related articles for article (PubMed ID: 37494443)
1. Lysosomal dysfunction in Down syndrome and Alzheimer mouse models is caused by v-ATPase inhibition by Tyr Im E; Jiang Y; Stavrides PH; Darji S; Erdjument-Bromage H; Neubert TA; Choi JY; Wegiel J; Lee JH; Nixon RA Sci Adv; 2023 Jul; 9(30):eadg1925. PubMed ID: 37494443 [TBL] [Abstract][Full Text] [Related]
2. Lysosomal Dysfunction in Down Syndrome Is APP-Dependent and Mediated by APP-βCTF (C99). Jiang Y; Sato Y; Im E; Berg M; Bordi M; Darji S; Kumar A; Mohan PS; Bandyopadhyay U; Diaz A; Cuervo AM; Nixon RA J Neurosci; 2019 Jul; 39(27):5255-5268. PubMed ID: 31043483 [TBL] [Abstract][Full Text] [Related]
3. Alzheimer's-related endosome dysfunction in Down syndrome is Abeta-independent but requires APP and is reversed by BACE-1 inhibition. Jiang Y; Mullaney KA; Peterhoff CM; Che S; Schmidt SD; Boyer-Boiteau A; Ginsberg SD; Cataldo AM; Mathews PM; Nixon RA Proc Natl Acad Sci U S A; 2010 Jan; 107(4):1630-5. PubMed ID: 20080541 [TBL] [Abstract][Full Text] [Related]
4. Targeting increased levels of APP in Down syndrome: Posiphen-mediated reductions in APP and its products reverse endosomal phenotypes in the Ts65Dn mouse model. Chen XQ; Salehi A; Pearn ML; Overk C; Nguyen PD; Kleschevnikov AM; Maccecchini M; Mobley WC Alzheimers Dement; 2021 Feb; 17(2):271-292. PubMed ID: 32975365 [TBL] [Abstract][Full Text] [Related]
5. Evidence that the rab5 effector APPL1 mediates APP-βCTF-induced dysfunction of endosomes in Down syndrome and Alzheimer's disease. Kim S; Sato Y; Mohan PS; Peterhoff C; Pensalfini A; Rigoglioso A; Jiang Y; Nixon RA Mol Psychiatry; 2016 May; 21(5):707-16. PubMed ID: 26194181 [TBL] [Abstract][Full Text] [Related]
6. Partial BACE1 reduction in a Down syndrome mouse model blocks Alzheimer-related endosomal anomalies and cholinergic neurodegeneration: role of APP-CTF. Jiang Y; Rigoglioso A; Peterhoff CM; Pawlik M; Sato Y; Bleiwas C; Stavrides P; Smiley JF; Ginsberg SD; Mathews PM; Levy E; Nixon RA Neurobiol Aging; 2016 Mar; 39():90-8. PubMed ID: 26923405 [TBL] [Abstract][Full Text] [Related]
7. Dual-specificity tyrosine(Y)-phosphorylation regulated kinase 1A-mediated phosphorylation of amyloid precursor protein: evidence for a functional link between Down syndrome and Alzheimer's disease. Ryoo SR; Cho HJ; Lee HW; Jeong HK; Radnaabazar C; Kim YS; Kim MJ; Son MY; Seo H; Chung SH; Song WJ J Neurochem; 2008 Mar; 104(5):1333-44. PubMed ID: 18005339 [TBL] [Abstract][Full Text] [Related]
8. Dysfunction of autophagy and endosomal-lysosomal pathways: Roles in pathogenesis of Down syndrome and Alzheimer's Disease. Colacurcio DJ; Pensalfini A; Jiang Y; Nixon RA Free Radic Biol Med; 2018 Jan; 114():40-51. PubMed ID: 28988799 [TBL] [Abstract][Full Text] [Related]
9. Endolysosomal impairment by binding of amyloid beta or MAPT/Tau to V-ATPase and rescue via the HYAL-CD44 axis in Alzheimer disease. Kim SH; Cho YS; Kim Y; Park J; Yoo SM; Gwak J; Kim Y; Gwon Y; Kam TI; Jung YK Autophagy; 2023 Aug; 19(8):2318-2337. PubMed ID: 36843263 [TBL] [Abstract][Full Text] [Related]
10. [Elucidating Pathogenic Mechanisms of Early-onset Alzheimer's Disease in Down Syndrome Patients]. Asai M; Kawakubo T; Mori R; Iwata N Yakugaku Zasshi; 2017; 137(7):801-805. PubMed ID: 28674290 [TBL] [Abstract][Full Text] [Related]
11. Autolysosomal acidification failure as a primary driver of Alzheimer disease pathogenesis. Lee JH; Nixon RA Autophagy; 2022 Nov; 18(11):2763-2764. PubMed ID: 35947489 [TBL] [Abstract][Full Text] [Related]
13. Normalizing the gene dosage of Dyrk1A in a mouse model of Down syndrome rescues several Alzheimer's disease phenotypes. García-Cerro S; Rueda N; Vidal V; Lantigua S; Martínez-Cué C Neurobiol Dis; 2017 Oct; 106():76-88. PubMed ID: 28647555 [TBL] [Abstract][Full Text] [Related]
14. Amyloid precursor protein-mediated endocytic pathway disruption induces axonal dysfunction and neurodegeneration. Xu W; Weissmiller AM; White JA; Fang F; Wang X; Wu Y; Pearn ML; Zhao X; Sawa M; Chen S; Gunawardena S; Ding J; Mobley WC; Wu C J Clin Invest; 2016 May; 126(5):1815-33. PubMed ID: 27064279 [TBL] [Abstract][Full Text] [Related]
15. Neuronal-Targeted TFEB Accelerates Lysosomal Degradation of APP, Reducing Aβ Generation and Amyloid Plaque Pathogenesis. Xiao Q; Yan P; Ma X; Liu H; Perez R; Zhu A; Gonzales E; Tripoli DL; Czerniewski L; Ballabio A; Cirrito JR; Diwan A; Lee JM J Neurosci; 2015 Sep; 35(35):12137-51. PubMed ID: 26338325 [TBL] [Abstract][Full Text] [Related]
16. Untangle the mystery behind DS-associated AD - Is APP the main protagonist? Elangovan A; Babu HWS; Iyer M; Gopalakrishnan AV; Vellingiri B Ageing Res Rev; 2023 Jun; 87():101930. PubMed ID: 37031726 [TBL] [Abstract][Full Text] [Related]